logo
  • About us
    • In brief
    • The Board of Directors
    • Management Team
    • Corporate Governance
    • Intellectual Properties
    • Partnerships
    • Environment & quality
    • Organization
    • Career
  • Project portfolio
    • Project overview
    • Research areas
    • Development phases
    • Publications
  • Contract research
    • Autoradiography
    • Pharmacokinetics
    • Analytical chemistry
    • Disease models
  • Investor info
    • Contacts
    • Press releases
    • Stock
    • Interim reports
    • Annual reports
    • Presentations
    • Ownership
    • Official documents
    • Calendar
  • Press & news
    • Press releases
    • Interim reports
    • Annual reports
    • Features
    • Image bank
    • Calendar
    • Contacts
  • Contact
    • Visit us
rss RSS
font size decrease font increase font

Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system.
We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments.

  • 2012-05-11 Annual General Meeting of Active Biotech AB
  • 2012-04-26 Active Biotech AB Interim report January - March 2012
  • 2012-04-17 Annual Report 2011 Active Biotech AB (publ)
  • 2012-04-11 Active Biotech: Notice of Annual General Meeting of Shareholders
  • 2012-03-15 Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients

Annual General Meeting 2012

For more information >>

Annual Report 2011

Read the report here >>

TASQ at the 27th Annual EAU Congress, Paris 24-28 February 2012

View the complete poster here >>

Subscribe to press releases from Active Biotech >>

Subscribe to press releases from Active Biotech >>
Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00